Neuphoria Therapeutics reported total assets of $28.71M and total liabilities of $4.11M for the quarter ended Jun 2026, up 0.4% year over year. This balance sheet covers 16 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Jun2020 | Jun2021 | Jun2022 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Current Assets | ||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 3.00M | 21.95M | 24.04M | 12.20M | 8.14M | 10.15M | 8.43M | 12.61M | 8.08M | 4.34M | 17.04M | 14.21M | 13.65M | 22.20M | 19.44M | 19.90M |
| Short-term InvestmentsInvestments (Current) | 0.34M | |||||||||||||||
| Cash & Current Investments | 3.00M | 22.28M | 24.04M | 12.20M | 8.14M | 10.15M | 8.43M | 12.61M | 8.08M | 4.34M | 17.04M | 14.21M | 13.65M | 22.20M | 19.44M | 19.90M |
| Receivables - NetNet Receivables | 0.69M | 0.15M | 0.05M | 0.01M | 0.13M | 0.12M | 0.04M | 0.02M | 0.01M | 0.00M | 1.11M | 1.61M | 0.81M | |||
| Receivables - OtherOther Receivables | 0.50M | 0.71M | 4.81M | 0.42M | 0.10M | 0.10M | 0.49M | 0.81M | 0.81M | |||||||
| Receivables | 1.19M | 0.87M | 4.86M | 0.43M | 0.22M | 0.22M | 0.04M | 0.02M | 0.01M | 0.00M | 1.60M | 2.41M | 1.62M | |||
| Prepaid Assets | 0.80M | 0.46M | 0.23M | 0.02M | 0.02M | 0.74M | 0.22M | 0.03M | 0.61M | 0.39M | ||||||
| Current Assets | 23.82M | 29.95M | 13.43M | 13.19M | 8.43M | 4.40M | 17.09M | 15.04M | 13.95M | 23.39M | 21.66M | 21.07M | ||||
| Non-Current Assets | ||||||||||||||||
| Property, Plant & Equipment (Net)PP&E (Net) | 1.32M | 0.01M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | ||||||
| Goodwill | 8.44M | 9.55M | 9.22M | 8.75M | 8.57M | 8.84M | 8.63M | 8.69M | 8.90M | 8.41M | 8.45M | 8.64M | 8.67M | 8.74M | 8.84M | 3.50M |
| Intangibles | 15.93M | 7.66M | 7.05M | 6.15M | 5.96M | 5.80M | 5.63M | 5.47M | 5.30M | 5.14M | 4.97M | 4.80M | 4.64M | 4.47M | 4.31M | 4.14M |
| Goodwill & Intangibles | 24.37M | 7.66M | 7.05M | 6.15M | 14.54M | 14.64M | 14.26M | 14.16M | 14.21M | 13.54M | 13.42M | 13.44M | 13.31M | 13.21M | 13.15M | 7.64M |
| Other Non-Current Assets | 0.08M | 0.08M | 0.08M | 0.08M | 0.08M | 0.07M | 0.07M | 0.08M | 0.08M | 0.08M | ||||||
| Non-Current Assets | 17.97M | 16.83M | 15.31M | 14.46M | 14.49M | 13.77M | 13.62M | 13.55M | 13.39M | 13.21M | 13.15M | 7.64M | ||||
| Assets | 0.72M | 41.79M | 46.78M | 28.74M | 27.65M | 22.92M | 18.17M | 30.71M | 28.59M | 27.34M | 36.60M | 34.81M | 28.71M | |||
| Liabilities | ||||||||||||||||
| Current Liabilities | ||||||||||||||||
| Accounts Payables | 1.52M | 1.40M | 2.00M | 2.34M | 2.24M | 1.33M | 1.53M | 0.75M | 1.15M | 1.37M | 0.52M | 0.63M | 0.39M | |||
| Payables | 1.52M | 1.40M | 2.00M | 2.34M | 2.24M | 1.33M | 1.53M | 0.75M | 1.15M | 1.37M | 0.52M | 0.63M | 0.39M | |||
| Accumulated Expenses | 1.19M | 1.46M | 1.10M | 0.79M | 0.68M | 2.95M | 3.67M | 2.07M | 0.89M | 0.37M | ||||||
| Other Accumulated Expenses | 0.04M | 0.31M | 0.08M | 0.03M | 0.03M | 0.28M | 0.11M | 0.10M | 0.17M | 0.05M | ||||||
| Total Current Liabilities | 1.82M | 2.40M | 2.76M | 3.83M | 2.55M | 2.13M | 1.55M | 4.22M | 5.12M | 2.59M | 1.51M | 0.76M | ||||
| Non-Current Liabilities | ||||||||||||||||
| Non-Current Deferred Tax LiabilityNon-Current Deferred Tax | 1.10M | 0.96M | 0.83M | 0.84M | 0.76M | 0.50M | 0.46M | 0.43M | 0.39M | 0.36M | ||||||
| Operating Leases | 0.02M | 0.53M | 0.38M | 0.24M | 0.12M | 0.09M | 0.05M | 0.02M | ||||||||
| Other Non-Current Liabilities | 2.46M | 4.66M | 1.69M | 0.81M | 1.89M | 3.70M | 8.09M | 2.71M | 2.46M | 1.97M | ||||||
| Total Non-Current Liabilities | 3.32M | 3.61M | 3.83M | 5.50M | 4.16M | 3.61M | 2.83M | 5.89M | 6.74M | 4.18M | 2.93M | 2.14M | ||||
| Total Liabilities | -7.60M | 5.13M | 6.01M | 6.59M | 10.16M | 5.85M | 4.42M | 4.72M | 9.59M | 14.83M | 6.90M | 5.39M | 4.11M | |||
| Shareholder's Equity | ||||||||||||||||
| Common Equity | 8.31M | 36.65M | 40.76M | 22.15M | 17.23M | 19.50M | 17.95M | 17.49M | 17.07M | 13.75M | 26.00M | 19.00M | 12.51M | 29.70M | 29.42M | 24.60M |
| Liabilities and Shareholders Equity | 0.72M | 41.79M | 46.78M | 28.74M | 27.65M | 22.92M | 18.17M | 30.71M | 28.59M | 27.34M | 36.60M | 34.81M | 28.71M | |||
| Retained Earnings | -136.86M | -177.98M | -178.80M | -180.73M | -169.50M | -178.35M | -188.30M | -186.40M | -186.90M | -191.80M |
Pull Neuphoria Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=NEUP&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "NEUP", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=NEUP&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();